(Public, NASDAQ:TSRO)   Watch this stock  
Find more results for Timothy Pearson´┐Ż
+2.83 (5.93%)
After Hours: 50.54 0.00 (0.00%)
Nov 25, 4:24PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 47.44 - 50.79
52 week 32.95 - 66.95
Open 47.72
Vol / Avg. 395,222.00/524,086.00
Mkt cap 1.91B
P/E     -
Div/yield     -
EPS -5.81
Shares 40.09M
Beta 1.46
Inst. own 116%
Feb 17, 2016
Q4 2015 TESARO Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 18, 2015
TESARO Inc at Jefferies Global Healthcare Conference - Webcast
Nov 10, 2015
TESARO Inc at Credit Suisse Healthcare Conference
Nov 4, 2015
TESARO Inc at Citi Global Healthcare Conference
Oct 29, 2015
Q3 2015 TESARO Inc Earnings Call - Webcast
Oct 29, 2015
Q3 2015 TESARO Inc Earnings Release
Oct 15, 2015
TESARO Inc Conference Call with Clients of Leerink Partners
Oct 1, 2015
TESARO Inc at Leerink Partners Immuno-Oncology Roundtable
Sep 10, 2015
TESARO Inc at Robert W Baird and Co Health Care Conference
Sep 10, 2015
TESARO Inc at Citi Biotech Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -76535.63% -
Operating margin -72117.24% -
EBITD margin - -
Return on average assets -78.76% -85.62%
Return on average equity -149.35% -138.35%
Employees 108 -
CDP Score - -


1000 Winter St Ste 3300
WALTHAM, MA 02451-1230
United States - Map
+1-339-9700900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
Mary Lynne Hedley Ph.D. President, Chief Operating Officer, Director
Age: 52
Bio & Compensation  - Reuters
Leon O. Moulder Jr. Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Timothy R. Pearson Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Joseph L. Farmer Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Martin Huber M.D. Senior Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
James O. Armitage M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Garry A Nicholson Independent Director
Bio & Compensation  - Reuters
Arnold L. Oronsky Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Beth C. Seidenberg M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters